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Summary
Venous thromboembolism (VTE)-BLEED, a decision tool for predicting
major bleeding during chronic anticoagulation for VTE has not yet been
validated in practice-based conditions. We calculated the prognostic indices
of VTE-BLEED for major bleeding after day 30 and day 90, as well as for
recurrent VTE and all-cause mortality, in 4457 patients enrolled in the
international, prospective XALIA study. The median at-risk time was
190 days (interquartile range 106–360). The crude hazard ratio (HR) for
major bleeding after day 30 was 26 [95% confidence interval (CI) 13–52]
and the treatment-adjusted HR was 23 (95% CI 11–45) for VTE-BLEED
high (versus low) risk patients: the corresponding values for major bleeding
after day 90 were 38 (95% CI 16–93) and 32 (95% CI 13–77), respec-
tively. The predictive value of VTE-BLEED was similar in selected patients
with unprovoked VTE or those treated with rivaroxaban. High VTE-
BLEED score was associated with higher incidence of all-cause mortality
(treatment-adjusted HR 11, 95% CI 48–23), but not evidently with recur-
rent VTE (treatment-adjusted HR 15; 95% CI 085–27). These results con-
firm the predictive value of VTE-BLEED in practice-based data in patients
treated with rivaroxaban or conventional anticoagulation, supporting the
hypothesis that VTE-BLEED may be useful for making management deci-
sions on the duration of anticoagulant therapy.
Keywords: venous thromboembolism, bleeding, anticoagulation therapy.
rivaroxaban, prediction.
Current international guidelines recommend discontinuing
anticoagulant therapy for unprovoked acute pulmonary
embolism (PE) or deep vein thrombosis (DVT) after the first
3 months of treatment only in patients considered at high
risk of bleeding (Konstantinides et al, 2014; Kearon et al,
2016). However, it remains challenging to quantify the indi-
vidual risk of major bleeding and although risk assessment
models have been developed in the past years, they still,
without exception, lack sufficient validation in cohort and
management studies (Klok et al, 2015).
We recently derived and externally validated VTE-BLEED,
a simple 6-variable risk score designed to predict the risk of
major bleeding in patients with venous thromboembolism
(VTE) on stable, long-term anticoagulation (Table I) (Klok
et al, 2016). VTE-BLEED was first derived from patients ran-
domized to treatment with dabigatran in the RE-COVER tri-
als (Schulman et al, 2009, 2014). As the first validation step,
the score was further evaluated in warfarin-treated patients
from the same trial programme. In a subsequent study, VTE-
BLEED was tested in both treatment arms of the HOKUSAI-
VTE trial, namely in edoxaban- and warfarin-treated patients
(Hokusai VTE Investigators, 2013). In both the derivation
and validation studies, the odds ratio (OR) for major bleed-
ing in patients categorized in the VTE-BLEED high risk
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group compared to the low risk group ranged between 31
and 65, indicating a substantial increased risk in patients
with two or more VTE-BLEED points (Klok et al, 2016,
2017). These risk estimates remained the same when only
fatal or intracranial bleeding events were considered (Klok
et al, 2018). Based on these findings, VTE-BLEED is the only
available externally validated bleeding score for VTE patients
that has been tested in patients receiving vitamin K antago-
nists and direct thrombin inhibitors as well as direct factor
Xa inhibitors, across several relevant patient subcategories.
Nonetheless, the score still needs validation in practice-based
conditions before it can be integrated in the decision algo-
rithms of future management studies on the optimal dura-
tion of anticoagulant therapy in VTE patients.
In the current study, we aimed to assess the predictive
accuracy of VTE-BLEED for major bleeding during long-
term anticoagulant therapy in patients with DVT with or
without concurrent acute PE enrolled in the multicentre,
international, prospective, non-interventional XALIA study
(Ageno & Turpie, 2016; Ageno et al, 2016). We additionally
compared the incidences of recurrent VTE and death
between the VTE-BLEED low and high risk cohorts.
Patients and methods
Study setting and patients
The design of the XALIA study and patients’ selection crite-
ria were published elsewhere (Ageno et al, 2014). In short,
patients with a confirmed DVT aged 18 years or older and
with an indication (and no contraindication) for anticoagu-
lant treatment duration of at least 3 months were eligible for
inclusion. DVT was confirmed according to current diagnos-
tic standards. Patients were treated with either rivaroxaban
or conventional anticoagulation therapy, starting with a
course of parenteral anticoagulants, usually followed by a
vitamin K antagonist. The decision to treat a patient with
rivaroxaban or conventional anticoagulants was at the
attending physician’s discretion. The institutional review
boards of all participating hospitals approved the study and
all patients provided written informed consent.
Patients were followed for at least 12 months or until they
died. Major bleeding was defined as overt bleeding associated
with a decrease in haemoglobin of 20 g/l or more, or requiring
a transfusion of two or more units of blood (or red blood cell
concentrates), occurred in a critical site (i.e. intracranial,
intraspinal, intraocular, pericardial, intra-articular, intramus-
cular with compartment syndrome, retroperitoneal), or con-
tributed to death, based on the on the criteria of the
International Society on Thrombosis and Haemostasis (ISTH)
(Schulman & Kearon, 2005). Recurrent VTE was defined as
new-onset symptoms of DVT or PE with the final diagnosis
confirmed by objective tests according to the current standard
or death in which PE could not be ruled out or an autopsy
confirmed PE as the primary cause of death. All outcome
events were adjudicated by the independent Clinical Events
Committee whose members were unaware of the treatment
assignment. Only treatment-emergent events, i.e. events occur-
ring up to 2 days after terminating active anticoagulant treat-
ment, were included in this post-hoc analysis.
The current study excluded all patients who (i) did not
use anticoagulant treatment beyond the first 30 days, (ii)
who died or experienced recurrent VTE or major bleeding
during the first 30 days and (iii) those who received a vita-
min K antagonist for 1–14 days or parenteral anticoagulation
for 3–14 days before they were switched to rivaroxaban
(‘early switchers’) (Klok et al, 2016).
VTE-BLEED
The 6-variable VTE-BLEED score (Table I) was calculated
for all patients from the baseline variables. Renal insuffi-
ciency was defined as an estimated glomerular filtration rate
(eGFR) <60 ml/min, and uncontrolled arterial hypertension
as a systolic blood pressure ≥140 mmHg. A score of ≥2
points served to identify those patients at a predicted high
risk of bleeding (Klok et al, 2016).
Primary aim
The primary aim of the current analysis was to validate
VTE-BLEED in both the overall XALIA study population
and in each treatment arm of XALIA separately. We calcu-
lated the prognostic indices for VTE-BLEED for major
Table I. The VTE-BLEED score with original definition of variables
(Klok et al, 2016).
Factor Score
Active cancer* 2
Male with uncontrolled arterial hypertension† 1
Anaemia‡ 15
History of bleeding§ 15
Age ≥60 years old 15
Renal dysfunction¶ 15
Classification of patients with the VTE-BLEED score
Low bleeding risk Total score <2
High bleeding risk Total score ≥2
*Cancer diagnosed within 6 months before diagnosis of venous
thromboembolism (VTE) (excluding basal-cell or squamous-cell car-
cinoma of the skin), recently recurrent or progressive cancer or any
cancer that required anti-cancer treatment within 6 months before
the VTE was diagnosed.
†Males with uncontrolled arterial hypertension were defined by val-
ues of systolic blood pressure ≥140 mmHg at baseline.
‡Haemoglobin <130 g/l in men or <120 g/l in women.
§Including prior major or non-major clinically relevant bleeding
event, rectal bleeding, frequent nose bleeding, or haematuria.
¶An estimated glomerular filtration rate (eGRF) <60 ml/min defined
the presence of renal dysfunction: eGRF was calculated at baseline
with the Cockcroft-Gault formula, which include serum creatinine,
age, and body weight.
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bleeding occurring after day 30 and after day 90 as proxy for
long-term stable anticoagulation. Also, a subgroup analysis of
patients with unprovoked VTE was planned. Unprovoked
VTE was defined as the absence of recent surgery
(<3 months), recent trauma/fracture (<3 months), pregnancy
or post-partum (<3 months), post-thrombotic syndrome,
central venous catheter, recent immobilization and/or use of
oral contraceptives or hormone replacement therapy (Ageno
et al, 2014).
Secondary aims
The secondary aims of the current analysis included evalua-
tion of the main study outcome in patient subgroups strati-
fied by age, sex and presence of cancer (Turpie et al, 2017).
Further, the predictive value of VTE-BLEED for both recur-
rent VTE and all-cause mortality was evaluated after day 30.
Also, a sensitivity analysis was performed in a subgroup of
patients treated with either 20 mg rivaroxaban once daily or
a vitamin K antagonist, excluding patients treated with
reduced dosed rivaroxaban or long-term parenteral anticoag-
ulation.
Statistical analysis
For the presentation of the baseline characteristics, continu-
ous variables are described with means and standard devia-
tion, and categorical variables are presented as proportions
(n/N) and percentage (%). The absolute number and inci-
dence proportions of major bleeding, recurrent VTE and
all-cause mortality after day 30 (and day 90) are presented.
The at-risk period for events was defined as the period
between Day 31 (or Day 91) and treatment stop plus
2 days. Missing values of the baseline characteristics neces-
sary to calculate VTE-BLEED were replaced using multivari-
ate imputation by chained equations (full imputation using
a single chain with 200 imputations, 500 burn-in samples
and 500 updates between imputations) (Schafer, 1997).
Crude ORs for each increase of one point in VTE-BLEED
were calculated for the overall population and the prede-
fined subgroups. A logistic model with VTE-BLEED and
treatment arm as explanatory variables was applied to pre-
sent adjusted ORs as well. Cox regression analyses were per-
formed to calculate the hazard ratio (HR) of patients
categorized as high risk of bleeding by VTE-BLEED for all
outcomes. A Cox regression model using VTE-BLEED and
treatment group as covariates was applied to calculate
adjusted HRs. The diagnostic quality of the VTE-BLEED
score was further evaluated using receiver operator charac-
teristic (ROC) curve derived c-statistics.
Lastly, decision curve analyses were performed in order
to estimate the range of threshold probabilities in which
VTE-BLEED may provide a net benefit over standard man-
agement considering only major bleeding events (Fitzgerald
et al, 2015; Klok et al, 2017). The assumptions included
treatment according to VTE-BLEED works better than two
extreme scenarios, considering that ‘all’ or ‘none of’ patients
are treated, and assuming that anticoagulation in patients
classified in the high-risk VTE-BLEED group will be discon-
tinued. The net benefit (y-axis of the graph) of the decision
curve analyses indicates the number of additional true posi-
tives, i.e. patients with bleeding who were correctly classi-
fied as high risk, identified by VTE-BLEED (001 = 1
additional true positive high-risk patients out of 100
patients) without additional false positive cases. In the pre-
sent analysis, we studied the estimated net benefit of VTE-
BLEED with the strategies of ‘assuming all patients at high
risk’ or ‘assuming all patients at low risk’ within a range of
threshold probabilities. SAS 9.4 software (SAS Institute,
Cary, NC, USA) was used for the analysis of data. A two-
sided P < 005 was considered to be statistically significant.
Due to the retrospective character of the study no formal
hypothesis test was performed and all P-values should be
interpreted descriptively.
Results
Study patients
From the 5142 patients included in XALIA, 368 were
excluded because they were classified as ‘early switchers’, six
because they did not take study medication and 311 because
they experienced one of the study outcomes or stopped treat-
ment before day 30 after VTE diagnosis, leaving 4457
patients for the primary analysis. Of these, 804 patients
(18%) were treated after day 30 and for at least a part of the
observation period, with low (less than 20 mg once daily)
doses of rivaroxaban, or received prolonged parenteral treat-
ment with heparin. The remaining 3653 patients (82%), who
received the ‘standard’ therapeutic rivaroxaban dose of
20 mg once daily or an International Normalised Ratio-tar-
geted (20–30) vitamin K antagonist after day 30, formed
the population of the sensitivity analysis. Baseline characteris-
tics of the study population are shown in Table II. Of all
patients in the primary analysis, 63% were classified into the
VTE-BLEED low-risk group. This was 72% for patients in
the rivaroxaban cohort and 53% in the standard of care
cohort.
Adverse events
Of all 4457 patients available for the primary analysis, 39
patients (088%) experienced a major bleeding event after
day 30 during a median at-risk time of 190 days [interquar-
tile range (IQR) 106–360 days]. This percentage was 045%
in the rivaroxaban-treated group and 14% in the standard
of care group. Major bleeding after day 90 was diagnosed in
068% of all patients. A total of 55 (12%) patients suffered
recurrent VTE on anticoagulant treatment and 84 (19%)
died (Table III).
Validation of VTE-BLEED in Practice-based Data
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Primary outcome
The absolute incidence of major bleeding after day 30 was
053% [15/2818, 95% confidence interval (CI) 032–088] in
the low-risk VTE group and 15% (24/1629, 95% CI 098–
22) in the high-risk group for a crude OR of 14 (95% CI
12–17) per increase of the VTE-BLEED score by one point.
This crude OR was 15 (95% CI 11–22) in the rivaroxaban
group and 13 (95% CI 11–16) in the standard of care
group, respectively (Table IV). The c-statistic was 068 (95%
CI 059–077) in the overall cohort, 069 (95% CI 055–084)
in the rivaroxaban group, and 064 (95% CI 052–075) in
the standard of care group. The crude HR for major bleeding
after day 30 was 26 (95% CI 13–52) and the treatment-
adjusted HR was 23 (95% CI 11–45) comparing the high-
risk versus the low-risk VTE-BLEED group.
The overall crude and treatment-adjusted OR per point
increase for major bleeding after day 90 were 15 (95% CI
12–19) and 14 (95% CI 11–17), whereas the crude and
treatment-adjusted HR were 38 (95% CI 16–93) and 32
(95% CI 13–77 comparing the high-risk vs. the low-risk
VTE-BLEED group; Table V), respectively. The c-statistic for
major bleeding after day 90 was 071 (95% CI 061–082).
The predictive value of VTE-BLEED in patients with
unprovoked VTE was comparable to that of the overall
Patients for primary analysis (n = 4457)
Age (years), mean (SD) 60 (17)
Female, n (%) 2065 (46)
Length of at-risk period (days), median (IQR) 190 (106–360)
DVT only, n (%) 4022 (90)
DVT plus PE, n (%) 435 (98)
Unprovoked DVT, n (%) 2860 (64)
Previous VTE, n (%) 1032 (23)
Active cancer, n (%) 500 (11)
First available eGFR, n (%)
<30 ml/min 63 (14)
30–50 ml/min 224 (50)
≥50 ml/min 2569 (58)
Missing 1601 (36)
Haemoglobin (g/l)
Mean (SD) 140 (17)
Missing, n (%) 1731 (39)
Systolic blood pressure (mmHg)
Mean (SD) 137 (19)
Missing, n (%) 2179 (49)
Previous major bleeding episode, n (%) 91 (20)
DVT, deep vein thrombosis; eGFR, estimated glomerular filtration rate; IQR, interquartile
range; PE, pulmonary embolism.
Table II. Baseline characteristics of study
patients.
Adverse event Treatment arm
Incidence, n (%)
Low risk High risk
Major bleeding after day 30 Rivaroxaban 6 (035) 5 (070)
Standard of care 9 (084) 19 (21)
Overall 15 (053) 24 (15)
Major bleeding after day 90 Rivaroxaban 2 (013) 3 (048)
Standard of care 6 (063) 16 (19)
Overall 8 (031) 19 (131)
Recurrent VTE after day 30 Rivaroxaban 14 (080) 5 (071)
Standard of care 13 (13) 23 (25)
Overall 27 (096) 28 (17)
All-cause mortality after day 30 Rivaroxaban 3 (019) 6 (081)
Standard of care 6 (054) 69 (74)
Overall 9 (032) 75 (46)
Table III. Occurrence of adverse events during
anticoagulation of 4457 patients available for
the primary analysis. Fatal pulmonary embo-
lism included unexplained deaths.
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population with a c-statistic of 064 (051–070; Table IV) for
the primary outcome and 071 (95% CI 058–084) for major
bleeding after day 90. The adjusted OR per point increase of
VTE-BLEED for major bleeding after day 30 and after day 90
were 13 (95% CI 10–17) and 15 (95% CI 11–20), respec-
tively (Tables IV and V).
Secondary outcomes
VTE-BLEED predicted major bleeding after day 30 was simi-
lar in subgroups stratified by age and sex, with wider confi-
dence intervals due to the smaller patient numbers
(Table VI). Increases in the score appeared to be less predic-
tive for patients with malignancy, probably because all were
(by definition) categorized as ‘high risk’.
Using the same threshold of ≥2 points as for prediction of
major bleeding, patients in the high risk VTE-BLEED group
had a notable significant treatment-adjusted HR for overall
mortality (11; 95% CI 48–23; Table V). Risk estimates for
recurrent VTE after day 30 remained non-significant. As with
the primary analysis, these point estimates of the OR and
HR for all-cause mortality and recurrent VTE were compara-
ble for patients with unprovoked VTE.
Sensitivity analysis
Of the patients evaluated in the sensitivity analysis, 68% were
categorized in the VTE-BLEED low-risk group. This was
73% for patients in the rivaroxaban 20 mg once daily cohort
and 60% in the vitamin K antagonist cohort. A total of 25
patients (069%) experienced a major bleeding event after
day 30 during a median at-risk time of 192 days (IQR 110–
367). This percentage was 041% in the rivaroxaban 20 mg
once daily group and 11% in the vitamin K antagonist
group (Table SI). Major bleeding after day 90 occurred in
051% of all patients. VTE-BLEED was associated with com-
parable risk estimates for the primary and secondary out-
comes and subgroup analysis to the primary analysis except
for overall mortality (Tables SI, SII and SIII). All analyses
were repeated in a dataset restricted to patients with no
missing data, with comparable results (data not shown).
Decision curve analysis
The decision curve analysis showed that management deci-
sion based on the categorization of patients into two risk
classes by VTE-BLEED, i.e. continue anticoagulation in low-
risk and discontinue in high-risk patients, was (considering
30-day major bleeding events only) better than discontinuing
the treatment in all patients (assumption that all are at high
bleeding risk) or in none (assumption that all are at low
bleeding risk) up to a threshold probability of 05–15% for
the risk of major bleeding after Day 30 (Fig 1). For example,
following Fig 1, in a population with an expected 09% abso-
lute incidence of major bleeding on treatment after Day 30,
using (compared with not using) VTE-BLEED would allow
the identification of three additional true major bleedings per
1000 subjects, without increasing the number of false positive
predictions and weighing for the relative harm of a false pos-
itive and false negative result.
Discussion
Our main finding is that in practice-based conditions, VTE-
BLEED can differentiate VTE patients with higher from those
with lower risk of major bleeding during long-term anticoag-
ulation treatment. This conclusion is based on the observed
significant ORs for each point increase in the score as well as
the relevant HRs after application of the dichotomized VTE-
BLEED threshold of ≥2 (versus <2) points. The prognostic
indices were comparable for the sub-analyses of major bleed-
ing occurring after day 90, between treatment with rivaroxa-
ban and vitamin K antagonists, and both for the overall
study population as well as for selected patients with unpro-
voked VTE, who comprised 64% of the overall study popula-
tion. Moreover, the c-statistics for major bleeding after day
90 was >070 for patients with unprovoked VTE, for whom
accurate prediction of major bleeding on long-term
Table IV. Primary study outcome (major bleeding after day 30 during anticoagulation of 4457 patients available for the primary analysis).
Overall Rivaroxaban Standard of care Unprovoked VTE
Number of patients in low risk group (absolute risk) 2818 (63%) 1770 (72%) 1048 (53%) 1765 (62%)
Number of patients in high risk group (absolute risk) 1629 (37%) 6977 (28%) 9322 (47%) 1091 (38%)
Crude OR for 1-point score increase (95% CI) 14 (12–17) 15 (11–22) 13 (11–16) 13 (10–18)
Adjusted OR for 1-point score increase (95% CI) 14 (11–16) n.a. n.a. 13 (10–17)
Crude HR ≥2 points (95% CI) 26 (13–52) 19 (056–65) 25 (10–58%) 19 (077–48)
Adjusted HR ≥2 points (95% CI) 23 (11–45) n.a. n.a. 17 (069–44)
PPV (95% CI) 15% (098–22%) 072% (031–17%) 21% (13–33%) 11% (063–19%)
NPV (95% CI) 995% (99–100%) 997% (99–100%) 991% (98–100%) 995% (99–100%)
c-statistic (95% CI) 068 (059–077) 069 (055–084) 064 (052–075) 064 (051–070)
95% CI, 95% confidence interval; HR, hazard ratio; n.a., not applicable; NPV, negative predictive value; OR, odds ratio; PPV, positive predictive
value; VTE, venous thromboembolism.
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anticoagulant therapy is most relevant. In general, VTE-
BLEED appears to be useful for a range of threshold proba-
bilities between 05% and 15% during at-risk time in
XALIA, which roughly translates to a yearly risk of major
bleeding between 11% and 34%, assuming constant risks.
This risk is a realistic estimation for treatment with direct
oral anticoagulants (DOAC) (lower limit) and vitamin K
antagonists (higher limit), emphasizing the potential rele-
vance of VTE-BLEED for day-to-day clinical practice.
We identified two notable differences between the current
study and the previous derivation and validation studies
(Klok et al, 2016, 2017), which were performed in the setting
of multinational randomized controlled trials. First, where
~25% of patients were categorized in the high-risk group in
previous studies, this was considerably higher in the XALIA
patients (37%) (Klok et al, 2016, 2017). Of note, XALIA
patients treated with rivaroxaban were less often categorized
as high risk (28%) than patients treated with conventional
anticoagulants (47%; OR 044, 95% CI 039–050). Second,
the prognostic indices of VTE-BLEED in the XALIA study
were qualitatively better for the patients treated with a
DOAC than for those subjected to conventional treatment,
in contrast to what was described earlier (Klok et al, 2016,
2017). The key explanation for both observations is that this
was not a randomized trial and patients with cancer in
XALIA were more often treated with conventional treatment
than with rivaroxaban (19% vs. 6%, P < 0001), where
patients with cancer constituted less than 5% of all patients
enrolled in the RE-COVER trials and HOKUSAI study
(Schulman et al, 2009, 2014; Hokusai VTE Investigators
2013). Patients with cancer are, by definition, categorized as
VTE-BLEED high risk and the majority of cases are treated
with parenteral anticoagulants. Until now, VTE-BLEED was
never tested for long-term treatment with low molecular
weight heparins. Importantly, the fact that the prognostic
indices observed in patients with unprovoked VTE and the
sensitivity analysis remained relevant, underlines the validity
of our conclusion.
Although the negative predictive value of a VTE-BLEED
score <20 points was very high (>995% for primary analy-
sis), the positive predictive value (PPV) of VTE-BLEED in
XALIA was low, with values ranging between 072% and
21% (Table IV). This limited PPV is explained by the rela-
tively low incidence of major bleeding during the study per-
iod (after day 30): 041% for rivaroxaban and 11% for
conventional treatment with vitamin K antagonists. Interest-
ingly and despite the fact that XALIA was an observational
study with less strict selection criteria than the phase 3 trials
with DOACs, these incidences of major bleeding compare
well to those observed in the RE-COVER trials (054% and
10% per 6 months for dabigatran and warfarin, respectively)
and HOKUSAI study (082% and 10% per 3–12 months for
edoxaban and warfarin, respectively) (Schulman et al, 2009,
2014; Hokusai VTE Investigators 2013; Klok et al, 2016,
2017). Even so, considering the 11% incidence of major
bleeding in the sensitivity analysis on warfarin treatment, the
incidences of major bleeding in XALIA do seem representa-
tive in the perspective of the established yearly 27% inci-
dence-rate of major bleeding in patients on long-term
vitamin K antagonist treatment (Linkins et al, 2003). The
strength of VTE-BLEED in this ‘real-world’ cohort of
patients thus lies predominantly in the identification of the
majority of patients with a very low risk of major bleeding,
in whom anticoagulants could be continued safely beyond
the first 3 months.
We also found that VTE-BLEED high-risk patients had a
higher incidence of all-cause mortality than low-risk patients
(Table V). This effect can be very likely explained by the
clustering of patients with more comorbid conditions in the
high-risk group, such as cancer and renal insufficiency. This
higher incidence of mortality could not be explained by
higher incidences of fatal bleeding, because this complication
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Fig 1. Decision curve analysis. Grey line represents scenario where VTE-BLEED is used to treat low risk patients but not high risk patients; Hori-
zontal black line represents scenario where all patients are assumed to be of low risk and none are treated with discontinuation of anticoagulants
(all receive anticoagulants); dashed grey line represents scenario in which all patients are assumed to be a high risk and all are treated with anti-
coagulant discontinuation (none receive anticoagulants); vertical long dashed black line represents prevalence of major bleeding in Rivaroxaban-
treated patients in the sensitivity analysis; vertical dotted dashed black line represents prevalence of major bleeding in vitamin K antagonist-trea-
ted patients in the sensitivity analysis. Grey shaded area represents the range of threshold probabilities for which use of VTE-BLEED is associated
with a net clinical benefit over not using the score. Importantly, risks of VTE are not taken into account. VTE, venous thromboembolism.
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occurred only rarely: no fatal bleeding events occurred in the
rivaroxaban-treated patients versus two in patients of the
standard anticoagulation group. Interestingly, VTE-BLEED
high-risk patients were not at a higher risk of recurrent VTE.
Nonetheless, the hazards for VTE recurrence on treatment in
patients with high and low VTE-BLEED score (HR 15; 95%
CI 072–32 for patients with unprovoked VTE) in this study
(Table V) indicate that one cannot exclude the lack of any
association with recurrent VTE off treatment. The present
decision curve analysis can therefore not fully consider the
spectrum of risks associated with anticoagulant discontinua-
tion.
How are our findings relevant for clinical practice? First of
all, this analysis supports the predictive value of VTE-BLEED
reported in the derivation and validation studies (Klok et al,
2016, 2017). It also demonstrates the good performance of
the score in patients treated with rivaroxaban and, impor-
tantly, supports the generalizability of VTE-BLEED beyond
clinical trial conditions. Current evidence therefore points
towards the conclusion that therapeutic-dose anticoagulant
treatment is safe in patients with unprovoked VTE catego-
rized as ‘low risk’ by VTE-BLEED. On the other hand, opti-
mal long-term management of VTE-BLEED high-risk
patients, i.e. to continue anticoagulant treatment or not,
needs to be determined in future randomized controlled
trials.
The strongpoint of this analysis is the unique design of
XALIA, being a large non-interventional study with a com-
parator arm, involving extensive baseline as well as follow-up
data, and most importantly, subjecting all events to blinded
adjudication. The limitations of our study include that some
data required to calculate VTE-BLEED was missing, which
was solved by performing imputation techniques. Further,
the prevalence of acute PE among the study patients was
low, and no patients with isolated acute PE were enrolled.
Although the authors have no reason to consider this a
major bias, i.e. no differences were found in the predictive
value of VTE-BLEED in PE versus DVT patients in previous
studies (Klok et al, 2016, 2017), it remains to be proven that
our current findings could be translated to patient popula-
tions involving PE patients. Lastly, even though we were able
to study over 4500 patients, this was a post-hoc analysis and
subgroup analyses were performed in considerably smaller
patient numbers. This resulted in wider 95% confidence
intervals that, on some occasions, crossed the line ‘of no dif-
ference’, although point estimates of the OR and HR
remained in the same order of magnitude for all sub-analyses
across all predefined study groups.
In conclusion, the current analysis confirms the accuracy
of VTE-BLEED in high-quality practice-based data in
patients treated with rivaroxaban or warfarin. These data
support the hypothesis that VTE-BLEED may be useful for
making management decisions on the duration of anticoagu-
lant therapy, although our findings should be interpreted
with caution due to the design of the study. Where long-
term anticoagulant treatment seems to be safe and appropri-
ate in patients with unprovoked VTE categorized as ‘low
risk’ by VTE-BLEED, involving 70–75% of all patients, fur-
ther outcome studies should determine the optimal long-
term therapeutic management of VTE-BLEED high risk
patients.
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